ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers

European Urology

Volumn 63, Issue 1, 2013, Pages 4-15

  Kamat, Ashish M ^a   Hegarty, Paul K ^b   Gee, Jason R ^c   Clark, Peter E ^d   Svatek, Robert S ^e   Hegarty, Nicholas ^b   Shariat, Shahrokh F ^f   Xylinas, Evanguelos ^f   Schmitz Dräger, Bernd J ^g   Lotan, Yair ^h   Jenkins, Lawrence C ⁱ   Droller, Michael ^j   Van Rhijn, Bas W ^k   Karakiewicz, Pierre I ^l  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g Urologie   (Germany)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^l UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Bladder cancer; Detection; Diagnosis; Markers; Recommendations; Screening

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CARCINOEMBRYONIC ANTIGEN; CASPASE 3; COMPLEMENT FACTOR H; CYCLINE; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEMOGLOBIN; INTERLEUKIN 6; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; NUCLEAR MATRIX PROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN; THROMBOSPONDIN 1; UVOMORULIN; VASCULOTROPIN;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; CYSTOSCOPY; DATA BASE; ERYTHROCYTE; EVIDENCE BASED PRACTICE; FOLLOW UP; HEMATURIA; HUMAN; NARROW BAND IMAGING; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

CYSTOSCOPY; DIAGNOSTIC TECHNIQUES, UROLOGICAL; HUMANS; MASS SCREENING; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84870543907     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.09.057     Document Type: Review

References (133)

1. American Cancer Society Cancer facts and figures 2012 2012 American Cancer Society Atlanta, GA
2. M. Soloway, and S. Khoury Bladder cancer: 2nd International Consultation on Bladder Cancer - Vienna ed. 2. 2012 ICUD-EAU Paris, France p. 432
3. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http://www.cebm.net/index.aspx?o=1025.
4. R. Chou, and T. Dana Screening adults for bladder cancer: update of the 2004 evidence review for the US Preventive Services Task Force 2010 US Preventive Services Task Force Rockville, MD
5. S.N. Datta, G.M. Allen, R. Evans, K.C. Vaughton, and M.G. Lucas Urinary tract ultrasonography in the evaluation of haematuria - a report of over 1,000 cases Ann R Coll Surg Engl 84 2002 203 205
6. T.J. Edwards, A.J. Dickinson, S. Natale, J. Gosling, and J.S. McGrath A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic BJU Int 97 2006 301 305 discussion 305
7. S.F. Mishriki, G. Nabi, and N.P. Cohen Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up Urology 71 2008 13 16
8. J.P. Britton, A.C. Dowell, and P. Whelan Dipstick haematuria and bladder cancer in men over 60: results of a community study BMJ 299 1989 1010 1012
9. M.A. Rodgers, S. Hempel, T. Aho, J.D. Kelly, J. Kleijnen, and M. Westwood Diagnostic tests used in the investigation of adult haematuria: a systematic review BJU Int 98 2006 1154 1160
10. M.H. Khadra, R.S. Pickard, M. Charlton, P.H. Powell, and D.E. Neal A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice J Urol 163 2000 524 527
11. K. Chlapoutakis, N. Theocharopoulos, S. Yarmenitis, and J. Damilakis Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systematic review and meta-analysis Eur J Radiol 73 2010 334 338
12. T.J. Edwards, A.J. Dickinson, J. Gosling, P.D. McInerney, S. Natale, and J.S. McGrath Patient-specific risk of undetected malignant disease after investigation for haematuria, based on a 4-year follow-up BJU Int 107 2011 247 252
13. M. Babjuk, V. Soukup, and M. Pesl Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma Urology 71 2008 718 722
14. V.B. Lokeshwar, T. Habuchi, and H.B. Grossman Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers Urology 66 Suppl 1 2005 35 63
15. G. Mowatt, S. Zhu, and M. Kilonzo Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer Health Technol Assess 14 2010 1 331 iii-iv
16. S. Bastacky, S. Ibrahim, S.P. Wilczynski, and W.M. Murphy The accuracy of urinary cytology in daily practice Cancer 87 1999 118 128
17. B. Planz, E. Jochims, T. Deix, H.P. Caspers, G. Jakse, and A. Boecking The role of urinary cytology for detection of bladder cancer Eur J Surg Oncol 31 2005 304 308
18. G.D. Grossfeld, M.S. Litwin, and J.S. Wolf Jr. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up Urology 57 2001 604 610
19. T. Filbeck, U. Pichlmeier, R. Knuechel, W.F. Wieland, and W. Roessler Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors J Urol 168 2002 67 71
20. M. Kriegmair, D. Zaak, and K.H. Rothenberger Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy J Urol 168 2002 475 478
21. C.R. Riedl, D. Daniltchenko, F. Koenig, R. Simak, S.A. Loening, and H. Pflueger Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer J Urol 165 2001 1121 1123
22. S. Denzinger, M. Burger, and B. Walter Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study Urology 69 2007 675 679
23. Y. Fradet, H.B. Grossman, and L. Gomella A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study J Urol 178 2007 68 73 discussion 73
24. B. Geavlete, M. Jecu, R. Multescu, D. Georgescu, and P. Geavlete HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer - re-TURBT recurrence rates in a prospective, randomized study Urology 76 2010 664 669
25. H.B. Grossman, L. Gomella, and Y. Fradet A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178 2007 62 67
26. P. Jichlinski, L. Guillou, and S.J. Karlsen Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study J Urol 170 2003 226 229
27. D. Jocham, F. Witjes, and S. Wagner Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study J Urol 174 2005 862 866 discussion 866
28. J. Schmidbauer, F. Witjes, N. Schmeller, R. Donat, M. Susani, and M. Marberger Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
29. A. Stenzl, M. Burger, and Y. Fradet Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer J Urol 184 2010 1907 1913
30. R.T. Bryan, L.J. Billingham, and D.M. Wallace Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder BJU Int 101 2008 702 705 discussion 705-6
31. E.C. Cauberg, S. Kloen, and M. Visser Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer Urology 76 2010 658 663
32. H.W. Herr Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results BJU Int 105 2010 314 316
33. H.W. Herr, and S.M. Donat A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences BJU Int 102 2008 1111 1114
34. H.W. Herr, and S.M. Donat Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy BJU Int 107 2011 396 398
35. A. Naselli, C. Introini, F. Bertolotto, B. Spina, and P. Puppo Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer BJU Int 105 2010 208 211
36. K. Tatsugami, K. Kuroiwa, and T. Kamoto Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer J Endourol 24 2010 1807 1811
37. A. Shapiro, O.N. Gofrit, G. Pizov, J.K. Cohen, and J. Maier Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens Eur Urol 59 2011 106 112
38. Y. Pan, J.P. Lavelle, and S.I. Bastacky Detection of tumorigenesis in rat bladders with optical coherence tomography Med Phys 28 2001 2432 2440
39. G.J. Tearney, M.E. Brezinski, J.F. Southern, B.E. Bouma, S.A. Boppart, and J.G. Fujimoto Optical biopsy in human urologic tissue using optical coherence tomography J Urol 157 1997 1915 1919
40. A.C. Goh, N.J. Tresser, S.S. Shen, and S.P. Lerner Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer Urology 72 2008 133 137
41. B. Hermes, F. Spoler, and A. Naami Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion Urology 72 2008 677 681
42. A. Karl, H. Stepp, and E. Willmann Optical coherence tomography for bladder cancer - ready as a surrogate for optical biopsy? Results of a prospective mono-centre study Eur J Med Res 15 2010 131 134
43. M.J. Manyak, N.D. Gladkova, and J.H. Makari Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography J Endourol 19 2005 570 574
44. H. Ren, Z. Yuan, W. Waltzer, K. Shroyer, and Y. Pan Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography J Urol 184 2010 1499 1506
45. J. Schmidbauer, M. Remzi, and T. Klatte Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder Eur Urol 56 2009 914 919
46. V.K. Sengottayan, P. Vasudeva, and D. Dalela Intravesical real-time imaging and staging of bladder cancer: use of optical coherence tomography Indian J Urol 24 2008 592 593
47. E. Solsona, I. Iborra, and J.V. Ricos Recurrence of superficial bladder tumors in prostatic urethra Eur Urol 19 1991 89 92
48. G. Sonpavde, B.H. Goldman, and V.O. Speights Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
49. R. Ukai, E. Kawashita, and H. Ikeda A new technique for transurethral resection of superficial bladder tumor in 1 piece J Urol 163 2000 878 879
50. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Bladder cancer v.1.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
51. S. Baltaci, B. Resorlu, C. Yagci, K. Turkolmez, C. Gogus, and Y. Beduk Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma Urol Int 81 2008 399 402
52. A. Blanco Diez, M. Ruibal Moldes, and G. Suarez Pascual Staging of infiltrating bladder cancer. Role of C. T. scan [in Spanish] Arch Esp Urol 56 2003 23 29
53. S. Jaume, M. Ferrant, and B. Macq Tumor detection in the bladder wall with a measurement of abnormal thickness in CT scans IEEE Trans Biomed Eng 50 2003 383 390
54. J.K. Kim, S.Y. Park, H.J. Ahn, C.S. Kim, and K.S. Cho Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging Radiology 231 2004 725 731
55. M. Koplay, M. Kantarci, and F. Guven Diagnostic efficiency of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the assessment of bladder tumors after transurethral resection J Comput Assist Tomogr 34 2010 121 126
56. A. El-Assmy, M.E. Abou-El-Ghar, and A. Mosbah Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging Eur Radiol 19 2009 1575 1581
57. M. Matsuki, Y. Inada, F. Tatsugami, M. Tanikake, I. Narabayashi, and Y. Katsuoka Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results Eur Radiol 17 2007 201 204
58. X. Tillou, E. Grardel, and M. Fourmarier Can MRI be used to distinguish between superficial and invasive transitional cell bladder cancer [in French]? Prog Urol 18 2008 440 444
59. H. Watanabe, M. Kanematsu, and H. Kondo Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol 192 2009 1361 1366
60. N. Tuncbilek, M. Kaplan, and S. Altaner Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer AJR Am J Roentgenol 192 2009 949 955
61. I. Akmangit, H. Lakadamyali, A. Oto, H. Ozen, O. Akhan, and A. Besim Staging of urinary bladder tumors with CT and MRI [in Turkish] Tani Girisim Radyol 9 2003 63 69
62. F.J. Fernandez Mena, and Y.C. Moreno-Torres Bladder cancer [in Spanish] Arch Esp Urol 54 2001 493 510
63. M. Lodde, L. Lacombe, J. Friede, F. Morin, A. Saourine, and Y. Fradet Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma BJU Int 106 2010 658 663
64. M. Picchio, U. Treiber, and A.J. Beer Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings J Nucl Med 47 2006 938 944
65. A. Saokar, T. Islam, M. Jantsch, M.A. Saksena, P.F. Hahn, and M.G. Harisinghani Detection of lymph nodes in pelvic malignancies with computed tomography and magnetic resonance imaging Clin Imaging 34 2010 361 366
66. W.M. Deserno, M.G. Harisinghani, and M. Taupitz Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging Radiology 233 2004 449 456
67. M.G. Harisinghani, M.A. Saksena, and P.F. Hahn Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 186 2006 144 148
68. H.C. Thoeny, M. Triantafyllou, and F.D. Birkhaeuser Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients Eur Urol 55 2009 761 769
69. H. Ahlstrom, P.U. Malmstrom, H. Letocha, J. Andersson, B. Langstrom, and S. Nilsson Positron emission tomography in the diagnosis and staging of urinary bladder cancer Acta Radiol 37 1996 180 185
70. I.J. de Jong, J. Pruim, P.H. Elsinga, M.M. Jongen, H.J. Mensink, and W. Vaalburg Visualisation of bladder cancer using (11)C-choline PET: first clinical experience Eur J Nucl Med Mol Imaging 29 2002 1283 1288
71. A.B. Apolo, J. Riches, and H. Schoder Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer J Clin Oncol 28 2010 3973 3978
72. O. Drieskens, R. Oyen, H. Van Poppel, Y. Vankan, P. Flamen, and L. Mortelmans FDG-PET for preoperative staging of bladder cancer Eur J Nucl Med Mol Imaging 32 2005 1412 1417
73. A.S. Kibel, F. Dehdashti, and M.D. Katz Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 27 2009 4314 4320
74. B.P. Schrier, M. Peters, J.O. Barentsz, and J.A. Witjes Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer Eur Urol 49 2006 698 703
75. S. Yoshida, F. Koga, and S. Kawakami Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer Urology 75 2010 387 391
76. I.J. Liu, Y.H. Lai, and J.I. Espiritu Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy Urol Int 77 2006 69 75
77. Y. Lotan, and C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 61 2003 109 118 discussion 118
78. P.I. Karakiewicz, S. Benayoun, and C. Zippe Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder BJU Int 97 2006 997 1001
79. D. Tilki, M. Burger, and G. Dalbagni Urine markers for detection and surveillance of non-muscle-invasive bladder cancer Eur Urol 60 2011 484 492
80. Kip1, and α-catenin for progression in superficial bladder carcinoma Eur Urol 50 2006 76 82
81. K. Esuvaranathan, E. Chiong, and T.P. Thamboo Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha Cancer 109 2007 1097 1105
82. P.M. Moonen, B. van Balken-Ory, L.A. Kiemeney, J.A. Schalken, and J.A. Witjes Prognostic value of p53 for high risk superficial bladder cancer with long-term followup J Urol 177 2007 80 83
83. S.F. Shariat, Y. Lotan, and P.I. Karakiewicz p53 predictive value for pT1-2 N0 disease at radical cystectomy J Urol 182 2009 907 913
84. S.F. Shariat, C. Bolenz, and P.I. Karakiewicz p53 expression in patients with advanced urothelial cancer of the urinary bladder BJU Int 105 2010 489 495
85. P.J. Goebell, S.G. Groshen, and B.J. Schmitz-Drager p53 immunohistochemistry in bladder cancer - a new approach to an old question Urol Oncol 28 2010 377 388
86. W.M. Stadler, S.P. Lerner, and S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
87. S.F. Shariat, D.C. Chade, and P.I. Karakiewicz Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer J Urol 183 2010 68 75
88. Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. In press.
89. V. Margulis, Y. Lotan, and P.I. Karakiewicz Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114 119
90. S.F. Shariat, C. Bolenz, and G. Godoy Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol 182 2009 78 84 discussion 84
91. H.M. Behnsawy, H. Miyake, M.A. Abdalla, M.A. Sayed, F. Ahmed Ael, and M. Fujisawa Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection Urol Oncol 29 2011 495 501
92. J.P. Stein, D.A. Ginsberg, and G.D. Grossfeld Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer J Natl Cancer Inst 90 1998 1072 1079
93. S.F. Shariat, J. Kim, G. Raptidis, G.E. Ayala, and S.P. Lerner Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder Urology 61 2003 1140 1145
94. S.F. Shariat, A.R. Zlotta, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness Mod Pathol 20 2007 445 459
95. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma J Urol 177 2007 481 487 discussion 487
96. J.J. Del Pizzo, A. Borkowski, S.C. Jacobs, and N. Kyprianou Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival Am J Pathol 155 1999 1129 1136
97. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis Hum Pathol 37 2006 1568 1576
98. K. Yamana, V. Bilim, and N. Hara Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression Br J Cancer 93 2005 544 551
99. J.A. Karam, Y. Lotan, and P.I. Karakiewicz Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy Lancet Oncol 8 2007 128 136
100. F. Ong, L.M. Moonen, and M.P. Gallee Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53 Radiother Oncol 61 2001 169 175
101. I.J. Schultz, L.A. Kiemeney, and H.F. Karthaus Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas Clin Chem 50 2004 1425 1428
102. S.F. Shariat, R. Ashfaq, P.I. Karakiewicz, O. Saeedi, A.I. Sagalowsky, and Y. Lotan Survivin expression is associated with bladder cancer presence, stage, progression, and mortality Cancer 109 2007 1106 1113
103. S.F. Shariat, P.I. Karakiewicz, and G. Godoy Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study Clin Cancer Res 15 2009 7012 7019
104. B.H. Bochner, R.J. Cote, and N. Weidner Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1995 1603 1612
105. T.M. Jaeger, N. Weidner, and K. Chew Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer J Urol 154 1995 69 71
106. S.F. Shariat, R.F. Youssef, and A. Gupta Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers J Urol 183 2010 1744 1750
107. G.D. Grossfeld, D.A. Ginsberg, and J.P. Stein Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression J Natl Cancer Inst 89 1997 219 227
108. X. Zu, Z. Tang, Y. Li, N. Gao, J. Ding, and L. Qi Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis BJU Int 98 2006 1090 1093
109. Y. Miyata, S. Kanda, and K. Ohba Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D Clin Cancer Res 12 2006 800 806
110. H. Miyake, I. Hara, K. Gohji, K. Yoshimura, S. Arakawa, and S. Kamidono Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line Cancer Lett 123 1998 121 126
111. K. Mellon, C. Wright, P. Kelly, C.H. Horne, and D.E. Neal Long-term outcome related to epidermal growth factor receptor status in bladder cancer J Urol 153 1995 919 925
112. B.W.G. van Rhijn, T.C.M. Zuiverloon, and A.N. Vis Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer Eur Urol 58 2010 433 441
113. R.E. Jimenez, M. Hussain, and F.J. Bianco Jr. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 7 2001 2440 2447
114. W. Kassouf, P.C. Black, and T. Tuziak Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer J Urol 179 2008 353 358
115. C. Bolenz, S.F. Shariat, and P.I. Karakiewicz Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder BJU Int 106 2010 1216 1222
116. M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Ann Oncol 21 2010 815 819
117. A. Fleischmann, D. Rotzer, R. Seiler, U.E. Studer, and G.N. Thalmann Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours Eur Urol 60 2011 350 357
118. S. Boorjian, S. Ugras, and N.P. Mongan Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer Urology 64 2004 383 388
119. C. Mir, S.F. Shariat, and T.H. van der Kwast Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study BJU Int 108 2011 24 30
120. C. Tuygun, D. Kankaya, and A. Imamoglu Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression Urol Oncol 29 2011 43 51
121. C. Bolenz, Y. Lotan, R. Ashfaq, and S.F. Shariat Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder Eur Urol 56 2009 1093 1095
122. S.F. Shariat, J. Kim, C. Nguyen, T.M. Wheeler, S.P. Lerner, and K.M. Slawin Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer Urology 61 2003 359 364
123. S.F. Shariat, J.H. Kim, and B. Andrews Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma Cancer 92 2001 2985 2992
124. A. Castillejo, N. Rothman, and C. Murta-Nascimento TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis Int J Cancer 124 2009 608 613
125. R.S. Svatek, J.B. Shah, and J. Xing A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer Cancer 116 2010 4513 4519
126. T. Szarvas, M. Becker, and F. vom Dorp Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer Cancer Sci 101 2010 1300 1308
127. S.F. Shariat, M.A. Monoski, B. Andrews, T.M. Wheeler, S.P. Lerner, and K.M. Slawin Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder Urology 61 2003 1053 1058
128. B. Andrews, S.F. Shariat, J.H. Kim, T.M. Wheeler, K.M. Slawin, and S.P. Lerner Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer J Urol 167 2002 1475 1481
129. K. Matsumoto, S.F. Shariat, R. Casella, T.M. Wheeler, K.M. Slawin, and S.P. Lerner Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy J Urol 170 2003 2248 2252
130. D.J. Gallagher, M.I. Milowsky, and N. Ishill Detection of circulating tumor cells in patients with urothelial cancer Ann Oncol 20 2009 305 308
131. A. Gradilone, A. Petracca, and C. Nicolazzo Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer BJU Int 106 2010 710 715
132. M. Rink, F.K. Chun, and R. Dahlem Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study Eur Urol 61 2012 810 817
133. T.J. Guzzo, B.K. McNeil, T.J. Bivalacqua, D.J. Elliott, L.J. Sokoll, and M.P. Schoenberg The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy Urol Oncol 30 2012 44 48